Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib (2017)
Attributed to:
Wellcome Trust MRC Cambridge Stem Cell Institute
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.aam8060
PubMed Identifier: 28794285
Publication URI: http://europepmc.org/abstract/MED/28794285
Type: Journal Article/Review
Parent Publication: Science Translational Medicine
Issue: 402
ISSN: 1946-6234